|
Topic 371 - Phase I SBIR Contract - Valudation and Optimization of RP-185 as Adjuvant to Exploit the Immune Response Generated by Radiation
|
261201800023C
|
$299,847
|
$98,950
|
-, -
|
RIPTIDE BIOSCIENCE, INC.
|
|
Topic 375: Novel Diagnostic Imaging Modality for Monitoring Tumor Responses to a Hyperthermia Immunotherapy - Moonshot
|
261201800028C
|
$40,573
|
$13,389
|
-, -
|
IMAGO SYSTEMS, INC.
|
|
Training Program in Cancer Biology
|
5T32CA078207-13
|
$632,546
|
|
AARONSON, STUART
|
MOUNT SINAI SCHOOL OF MEDICINE
|
|
Modeling bladder cancer pathogenesis and tumor evolution
|
1P01CA221757-01A1
|
$1,765,498
|
$1,182,884
|
ABATE-SHEN, CORY
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Preclinical analyses of advanced prostate cancer in genetically-engineered mice
|
2R01CA173481-06
|
$385,883
|
$127,341
|
ABATE-SHEN, CORY
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Modeling androgen-independent prostate cancer in mutant mice
|
5R01CA115717-05
|
$296,723
|
$74,181
|
Abate-Shen, Cory
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Molecular mechanisms of prostate cancer metastasis
|
5R01CA183929-04
|
$366,000
|
$366,000
|
ABATE-SHEN, CORY
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Leadership Component in Chemoprevention: Mouse Models of Human Cancer Consortium
|
5U01CA141535-03
|
$402,325
|
|
Abate-Shen, Cory
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
BIOMOLECULAR ANALYSIS USING LIQUID CRYSTALS
|
5R01CA108467-07
|
$399,019
|
|
ABBOTT, NICHOLAS
|
UNIVERSITY OF WISCONSIN MADISON
|
|
Role of ASXL1 mutations in myeloid malignancies
|
1K08CA160647-01
|
$169,884
|
|
Abdel-Wahab, Omar
|
SLOAN-KETTERING INSTITUTE FOR CANCER RES
|
|
Modeling Prostate Tumorigenesis
|
5R01CA094858-09
|
$233,032
|
$116,516
|
Abdulkadir, Sarki
|
VANDERBILT UNIVERSITY
|
|
Gastric and Esophageal Malignancies in Northern Iran (GEMINI): Case-Control Study
|
ZIA CP000185-10318
|
$66,702
|
|
Abnet, Christian
|
DCEG (NCI)
|
|
IRF-8 as a Negative Regulator of CD11b+Gr-1+ Myeloid Cell Production and Function
|
1R01CA140622-01A2
|
$368,249
|
|
ABRAMS, SCOTT
|
ROSWELL PARK CANCER INSTITUTE CORP
|
|
Mechanisms Underlying Functional Programs of Tumor-Associated Macrophages
|
5R01CA172105-04
|
$401,456
|
$401,456
|
ABRAMS, SCOTT
|
ROSWELL PARK CANCER INSTITUTE CORP
|
|
Quantitative MRI for Predicting Response of Breast Cancer to Neoadjuvant Therapy
|
5U01CA142565-10
|
$461,172
|
$461,172
|
ABRAMSON, RICHARD
|
VANDERBILT UNIVERSITY MEDICAL CENTER
|
|
Role of TLR4 in colitis-associated neoplasia
|
5R01CA137869-03
|
$307,951
|
|
Abreu, Maria
|
UNIVERSITY OF MIAMI SCHOOL OF MEDICINE
|
|
Effects of Sema3A-Nrp1 signaling on tumor cell extravastion and metastasis
|
5K01CA148897-02
|
$108,467
|
$108,467
|
Acevedo, Lisette
|
UNIVERSITY OF CALIFORNIA SAN DIEGO
|
|
Center for Multiple Myeloma Nanotherapy
|
5U54CA199092-04
|
$2,184,301
|
$1,245,052
|
ACHILEFU, SAMUEL
|
WASHINGTON UNIVERSITY
|
|
Biophysical studies of oncogenic Cdc42Hs constructs
|
5K01CA113753-05
|
$146,324
|
$73,162
|
ADAMS, PAUL
|
UNIVERSITY OF ARKANSAS AT FAYETTEVILLE
|
|
Regulation of Oncogene-Induced Senescence by Wnt-Signaling
|
5R01CA129334-04
|
$195,639
|
|
ADAMS, PETER
|
UNIVERSITY OF GLASGOW
|
|
Redirecting T Cell Responses to Self/Tumor Antigens Using Enforced Costimulation
|
5R01CA109339-07
|
$76,871
|
$19,218
|
ADLER, ADAM
|
UNIVERSITY OF CONNECTICUT SCH OF MED/DNT
|
|
MMC, VICC & TSU: Partners in Eliminating Cancer Disparities (1 of 3)
|
5U54CA163069-08
|
$1,347,488
|
$256,023
|
ADUNYAH, SAMUEL
|
MEHARRY MEDICAL COLLEGE
|
|
Plumbagin in Combination with Vemurafenib for BRAF-mutant Melanoma
|
5R03CA212798-02
|
$74,250
|
$37,125
|
AFAQ, FARRUKH
|
UNIVERSITY OF ALABAMA AT BIRMINGHAM
|
|
Novel Combinatorial Therapeutic Approach for Prostate Cancer
|
5R03CA219336-02
|
$74,250
|
$37,125
|
AFAQ, FARRUKH
|
UNIVERSITY OF ALABAMA AT BIRMINGHAM
|
|
Colon Cancer Chemoprevention by Flavonoid Silibinin
|
2R01CA112304-06
|
$286,515
|
|
AGARWAL, RAJESH
|
UNIVERSITY OF COLORADO DENVER
|
|
Prostate Cancer Prevention by Procyanidins in Grape Seed Extract
|
5R01CA091883-09
|
$322,493
|
|
AGARWAL, CHAPLA
|
UNIVERSITY OF COLORADO DENVER
|
|
Prostate Cancer Prevention and Treatment by Silibinin
|
5R01CA102514-08
|
$322,493
|
$322,493
|
AGARWAL, RAJESH
|
UNIVERSITY OF COLORADO DENVER
|
|
Skin Cancer Chemoprevention by Silibinin: Mechanisms and Efficacy
|
5R01CA140368-02
|
$303,684
|
|
AGARWAL, RAJESH
|
UNIVERSITY OF COLORADO DENVER
|
|
SHP2-Mediated Synergy Between EGFR/HER2 and Beta Catenin in Breast Oncogenesis
|
5R01CA124940-05
|
$243,000
|
$80,190
|
AGAZIE, YEHENEW
|
WEST VIRGINIA UNIVERSITY
|
|
Elucidating the Role of STAT3-Dependent Autophagy in Hepatocellular Carcinoma
|
1F32CA162773-01
|
$48,398
|
|
Aghajan, Mariam
|
UNIVERSITY OF CALIFORNIA SAN DIEGO
|
|
Analysis of HCC CTC Phenotype for Liver Transplant Candidate Selection
|
1R21CA216807-01A1
|
$203,254
|
$203,254
|
AGOPIAN, VATCHE
|
UNIVERSITY OF CALIFORNIA LOS ANGELES
|
|
Magnetic Nanoparticles and Quantum Dots for Diagnosis of Early Stage Ovarian Canc
|
5R43CA154339-02
|
$141,192
|
|
AGUILAR, ZORAIDA
|
OCEAN NANOTECH, LLC
|
|
Clinical and Immunologic Evaluation of ProstAtak for Prostate Cancer
|
5R44CA124032-03
|
$1,902,504
|
|
Aguilar-Cordova, Estuardo
|
ADVANTAGENE, INC
|
|
Functional Determinants of Metastatic Dormancy
|
5R01CA109182-08
|
$317,129
|
$317,129
|
AGUIRRE-GHISO, JULIO
|
MOUNT SINAI SCHOOL OF MEDICINE
|
|
Functional Determinants of Metastatic Dormancy
|
5R01CA109182-15
|
$423,844
|
$423,844
|
AGUIRRE-GHISO, JULIO
|
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
|
|
Epigenetic and microenvironmental regulation of dormant disseminated cancer
|
5R01CA218024-02
|
$428,136
|
$214,068
|
AGUIRRE-GHISO, JULIO
|
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
|
|
Enhancing Bioavailability of Resveratrol
|
5R21CA149560-02
|
$187,979
|
|
Ahmad, Nihal
|
UNIVERSITY OF WISCONSIN MADISON
|
|
A Novel Therapeutic Approach for Primary and Metastatic Prostate Cancer
|
1R01CA150182-01A1
|
$296,474
|
$296,474
|
AHMED, KHALIL
|
UNIVERSITY OF MINNESOTA TWIN CITIES
|
|
Targeting galectin-3 to overcome drug resistance in metastatic prostate cancer therapy
|
1R43CA228813-01A1
|
$300,000
|
$300,000
|
AHMED, HAFIZ
|
GLYCOMANTRA, INC.
|
|
APC Tumor Suppressor in Cell Differentiation and Death
|
2R01CA105038-06A1
|
$266,280
|
|
Ahmed, Yasmath
|
DARTMOUTH COLLEGE
|
|
Modulating systemic pro-oncogenic effects of focal image-guided tumor ablation
|
5R01CA197081-03
|
$470,573
|
$155,289
|
AHMED, MUNEEB
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
Signal Transduction Pathways in Melanoma
|
5R01CA118972-05
|
$260,182
|
$208,146
|
Ahn, Natalie
|
UNIVERSITY OF COLORADO AT BOULDER
|
|
Chemoprevention of arsenic-induced skin cancer
|
5R01CA107431-07
|
$1,796,073
|
|
AHSAN, HABIBUL
|
UNIVERSITY OF CHICAGO
|
|
Epigenetic markers involved in colorectal cancer recurrence and metastases
|
5K23CA127141-04
|
$140,940
|
$70,470
|
AHUJA, NITA
|
JOHNS HOPKINS UNIVERSITY
|
|
The role of the SCF/FBW7 ubiquitin ligase complex in hematopiesis and leukemia
|
5R01CA133379-03
|
$341,161
|
|
AIFANTIS, IANNIS
|
NEW YORK UNIVERSITY SCHOOL OF MEDICINE
|
|
Mechanisms of T cell leukemia induction and maintenance
|
5R01CA149655-02
|
$340,155
|
$340,155
|
AIFANTIS, IANNIS
|
NEW YORK UNIVERSITY SCHOOL OF MEDICINE
|
|
Post-translational control of cancer cell stress response and metastasis
|
5R01CA202027-03
|
$459,505
|
$459,505
|
AIFANTIS, IANNIS
|
NEW YORK UNIVERSITY SCHOOL OF MEDICINE
|
|
Modifiers of Notch stability and their role in cancer
|
5R21CA141399-02
|
$178,275
|
|
AIFANTIS, IANNIS
|
NEW YORK UNIVERSITY SCHOOL OF MEDICINE
|
|
Downstream of Akt in the tumor vessel
|
5R01CA131152-04
|
$455,087
|
$150,179
|
Aird, William
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
Prediction of Pathologic Complete Response by Gene Expression Profiling in Esopha
|
5R01CA138671-02
|
$309,964
|
|
Ajani, Jaffer
|
UNIVERSITY OF TEXAS MD ANDERSON CAN CTR
|
Total relevant funding to Metastasis for this search: $719,804,994
|